Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | ACHE | P22303 | 3/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474018 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL3320662 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL29354627 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL339286 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL5143976 | 0.93 | DRD2 (0.86) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL8074250 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL7543711 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL8074280 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| Hydrochloric Acid SCHEMBL7932989 | 0.90 | DRD2 (0.81) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| Hydrochloric Acid SCHEMBL8604442 | 0.90 | DRD2 (0.81) | DRD2DRD3DRD4GRIN2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113969303-A | Preparation method of rotigotine intermediate | 上海天慈国际药业有限公司 | 2022-01-25 | — | — | CN | claimed |
| CN-113969303-A | Preparation method of rotigotine intermediate | 上海天慈国际药业有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | APOTEX INC. (CA) | 2017-10-26 | — | — | US | disclosed |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | APOTEX INC (CA) | 2016-10-13 | — | — | US | disclosed |
| WO-2016044918-A1 | PROCESSES FOR THE PREPARATION OF ROTIGOTINE AND INTERMEDIATES THEREOF | APOTEX INC. (CA) | 2016-03-31 | — | — | WO | disclosed |
| US-9145353-B2 | Method of preparing (S)-2-amino-5-methoxytetralin hydrochloride | ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) | 2015-09-29 | — | — | US | disclosed |
| US-20140046095-A1 | Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride | ANHUI KELONG INSTITUTE OF PHARMACEUTICAL (CN) | 2014-02-13 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| WO-2008116663-A2 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-02 | — | — | WO | disclosed |
| EP-1975161-A1 | Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-01 | — | — | EP | disclosed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956006-A1 | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1278885-B1 | RESOLUTION OF AMINOTETRALINS | TORCAN CHEMICAL LTD (CA) | 2004-06-16 | — | — | EP | disclosed |
| EP-1278885-A1 | RESOLUTION OF AMINOTETRALINS | TORCAN CHEMICAL Ltd (CA) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001083807-A1 | RESOLUTION OF AMINOTETRALINS | TORCAN CHEMICAL LTD. (CA) | 2001-11-08 | — | — | WO | disclosed |
| US-6271005-B1 | BY STEREOSPECIFIC ACYLATION BY THE ENZYME PSEUDOMONAS CEPACIA LIPASE OF ONE STEREOISOMER WHILE LEAVING THE OTHER UNCHANGED; 5-METHOXY-2-AMINOTETRALIN CHEMICAL INTERMEDIATES TO A 2-AMINOTETRALIN-ETHYLTHIOPHENE PARKINSON'S DRUG | TORCAN CHEMICAL LIMITED (CA) | 2001-08-07 | — | — | US | disclosed |
| WO-1991001957-A1 | RESOLUTION OF RACEMIC MIXTURES | ETHYL CORPORATION (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4968837-A | Resolution of racemic mixtures | ETHYL CORPORATION (US) | 1990-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140046095-A1 | Method of Preparing (S)-2-amino-5-Methoxytetralin Hydrochloride | ADRB2, TPMT, TDO2 | DRD2 44/4885DRD3 143/4885DRD4 96/4885 |
| US-20170305877-A1 | Processes for the Preparation of Rotigotine and Intermediates Thereof | C1S, C1R, C3AR1 | DRD2 119/4885DRD3 105/4885DRD4 126/4885 |
| US-20160297745-A1 | ENDODONTIC POST SYSTEM | ABCB11, EXOC3, C1S | DRD2 552/4885DRD3 125/4885DRD4 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.